371 related articles for article (PubMed ID: 29338277)
1. Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study.
Boskailo E; Malkoc A; McCurry DB; Venter J; Drachman D; Ramos GM
Acta Med Acad; 2017 Nov; 46(2):133-144. PubMed ID: 29338277
[TBL] [Abstract][Full Text] [Related]
2. Psychotropic medication changes, polypharmacy, and the risk of early readmission in suicidal adolescent inpatients.
Fontanella CA; Bridge JA; Campo JV
Ann Pharmacother; 2009 Dec; 43(12):1939-47. PubMed ID: 19934394
[TBL] [Abstract][Full Text] [Related]
3. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit.
Lerma-Carrillo I; de Pablo Brühlmann S; del Pozo ML; Pascual-Pinazo F; Molina JD; Baca-García E
Clin Neuropharmacol; 2008; 31(6):319-32. PubMed ID: 19050409
[TBL] [Abstract][Full Text] [Related]
6. Readmission Rates of Patients Discharged on Antipsychotic Polypharmacy Compared to Antipsychotic Monotherapy.
Greer D; Parikh A; Jimenez HR
Community Ment Health J; 2023 Apr; 59(3):507-511. PubMed ID: 36242684
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
Molina JD; Lerma-Carrillo I; Leonor M; Pascual F; Blasco-Fontecilla H; González-Parra S; López-Muñoz F; Alamo C
Clin Neuropharmacol; 2009; 32(1):10-5. PubMed ID: 18978498
[TBL] [Abstract][Full Text] [Related]
8. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and correlates of antipsychotic polypharmacy in Hong Kong.
Lung SLM; Lee HME; Chen YHE; Chan KWS; Chang WC; Hui LMC
Asian J Psychiatr; 2018 Mar; 33():113-120. PubMed ID: 29574303
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient Hospitals.
Ortiz G; Hollen V; Schacht L
J Psychiatr Pract; 2016 Jul; 22(4):283-97. PubMed ID: 27427840
[TBL] [Abstract][Full Text] [Related]
11. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study.
Kroken RA; Johnsen E; Ruud T; Wentzel-Larsen T; Jørgensen HA
BMC Psychiatry; 2009 May; 9():24. PubMed ID: 19445700
[TBL] [Abstract][Full Text] [Related]
12. Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes.
Weinmann S; Janssen B; Gaebel W
J Clin Psychiatry; 2004 Aug; 65(8):1099-105. PubMed ID: 15323596
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
[TBL] [Abstract][Full Text] [Related]
14. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of inpatient treatment continuation and hospital readmission rates in patients with bipolar disorder treated with aripiprazole or quetiapine.
Kreys TJ; Fabian TJ; Saul MI; Haskett R; Coley KC
J Psychiatr Pract; 2013 Jul; 19(4):288-95. PubMed ID: 23852103
[TBL] [Abstract][Full Text] [Related]
16. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.
Kreyenbuhl JA; Valenstein M; McCarthy JF; Ganoczy D; Blow FC
Psychiatr Serv; 2007 Apr; 58(4):489-95. PubMed ID: 17412850
[TBL] [Abstract][Full Text] [Related]
17. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
[TBL] [Abstract][Full Text] [Related]
18. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study.
Biancosino B; Barbui C; Marmai L; Donà S; Grassi L
Int Clin Psychopharmacol; 2005 Nov; 20(6):305-9. PubMed ID: 16192838
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution.
Procyshyn RM; Kennedy NB; Tse G; Thompson B
Can J Psychiatry; 2001 May; 46(4):334-9. PubMed ID: 11387789
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
Roh D; Chang JG; Kim CH; Cho HS; An SK; Jung YC
Aust N Z J Psychiatry; 2014 Jan; 48(1):52-60. PubMed ID: 23671214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
